Overview

A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

Status:
Recruiting

Trial end date:
2024-09-15

Target enrollment:

Participant gender:

Summary

To observe the efficacy and safety of a new generation of BTK inhibitor Orelabrutinib combined with PD-1 and fotemustine in the treatment of patients with primary central nervous system lymphoma (PCNSL).

Phase:

Phase 4

Details

Lead Sponsor:

Mingzhi Zhang

Treatments:

Fotemustine